Cocrystal Pharma's norovirus antiviral CDI-988 to be presented at MHSRS in August 2025

Cocrystal Pharma, Inc.

CDI-988, a broad-spectrum protease inhibitor, will be featured in an oral presentation at the 2025 Military Health System Research Symposium on August 4, 2025 in Kissimmee, Florida.
Cocrystal is developing CDI-988 as a norovirus prophylaxis and treatment; no approved antivirals or vaccines for norovirus currently exist.
President and co-CEO Sam Lee, PhD, will discuss Phase 1 safety, tolerability, and pharmacokinetics results at the conference.
CDI-988 targets a highly conserved region in 3CL viral proteases, potentially halting infection early regardless of viral strain or mutation.
Norovirus spreads rapidly in confined spaces like military settings, posing a threat to operational effectiveness and economic burden.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.